|  | | Interactions: |  | AllopurinolAdverse Effect: hypersensitivity reactions (Stevens-Johnson syndrome, skin eruptions)     
Clinical Management: If these drugs are used concurrently, monitor for hypersensitivity reactions.AmilorideAdverse Effect: hyperkalemia     Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.AspirinAdverse Effect: decreased captopril effectiveness     Clinical Management: Although studies have suggested an interaction between Perindopril and aspirin, the clinician should weigh the benefits against the risks of combining these two agents.BumetanideAdverse Effect: postural hypotension (first dose)    Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.CelecoxibAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.ChlorthalidoneAdverse Effect: postural hypotension (first dose)     Clinical Management: Start with a very low dose of Perindopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.ClopamideAdverse Effect: postural hypotension (first dose)     Clinical Management: Start with a very low dose of Perindopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.Diclofenac Preps.Adverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.ErythropoietinAdverse Effect: higher maintenance doses of erythropoietin to maintain the target hematocrit     Clinical Management: Monitor patients receiving angiotensin converting enzyme inhibitors for erythropoietin efficacy. When given concomitantly, doses of erythropoietin may be higher than expected.FlurbiprofenAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.FrusemideAdverse Effect: postural hypotension (first dose)     Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.IbuprofenAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.IndapamideAdverse Effect: postural hypotension (first dose)     Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.IndomethacinAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.KetoprofenAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.KetorolacAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.LithiumAdverse Effect: Lithium toxicity (weakness, tremor, excessive thirst, confusion) and/or nephrotoxicity     Clinical Management: The combination of lithium and Perindopril should be avoided if possible, though the choice of an alternative antihypertensive agent that does not interact with lithium is limited. If lithium and Perindopril are used concurrently, serum lithium levels should be closely monitored and the patient followed for any symptoms of lithium toxicity.Mefenamic AcidAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.MeloxicamAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.NabumetoneAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.NaproxenAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.NimesulideAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.OxyphenbutazoneAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.ParacetamolAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.PhenacetinAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.PhenylbutazoneAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.PiroxicamAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.SpironolactoneAdverse Effect: hyperkalemia     Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.TenoxicamAdverse Effect: Decreased antihypertensive and natriuretic effects     Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.XipamideAdverse Effect: postural hypotension (first dose)     Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments. | 
 |  |